Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To learn about the effects of the drugs regorafenib and lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie rak jelita grubego
- •Zakończona operacja i całe zaplanowane leczenie wspomagające
- •Brak widocznych zmian nowotworowych w badaniach obrazowych (wykonanych w ciągu 28 dni)
- •Dodatni test na DNA z komórek nowotworowych we krwi (MRD)
- •Prawidłowe funkcje wątroby, nerek i układu krwiotwórczego
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na leczenie (ECOG 0-1)
- •Zgoda na stosowanie antykoncepcji (dla kobiet w wieku rozrodczym)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 27, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
MD Anderson Cancer Center
Houston, United States
Trial contact
Kanwal Raghav, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/28/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.